Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK

Trial Profile

Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2013

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Oct 2013 New trial record
    • 26 Sep 2013 Results have been published in Vaccine, according to a Medicines and Healthcare products Regulatory Agency (MHRA) media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top